Stock Events

Stock Events

AIM ImmunoTech

€0

0

+€0+0% Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HXB.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Incyte Corporation operates in the biopharmaceutical field focusing on the discovery, development, and commercialization of proprietary therapeutics, including those that affect the immune system's function, which competes with AIM's immunotherapy approaches.

Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including treatments that modulate the immune system, directly competing with AIM's product pipeline.

Moderna, Inc. focuses on mRNA-based therapies, some of which are designed to activate the immune system against cancer and infectious diseases, competing with AIM's immunotherapeutic strategies.

BioNTech SE operates in the field of mRNA technology and immunotherapy, developing treatments that stimulate the body's immune response, similar to AIM's focus, making them direct competitors in the immunotherapy space.

Novavax, Inc. is involved in the development of vaccines that stimulate the immune system, competing with AIM ImmunoTech's efforts in immune system modulation for disease prevention and treatment.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is known for its innovation in biotechnology, including the development of immune-modulating drugs, which places it in direct competition with AIM in the field of immunotherapies.

CytoDyn Inc. focuses on the development and commercialization of novel therapeutics for the treatment of immune, viral, and other serious diseases, competing with AIM's focus on immune-based therapies.

iBio, Inc. is a biotechnology company that focuses on developing plant-based biopharmaceuticals, including vaccines and therapeutic proteins that modulate the immune system, making it a competitor to AIM in the broader field of immune-based therapies.

About

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Show more...

CEO

Mr. Thomas K. Equels Esq., J.D., M.S.

Employees

21

Country

United Kingdom

ISIN

US00901B3033

Listings

0 Comments

Share your thoughts

FAQ

What is AIM ImmunoTech stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange AIM ImmunoTech stocks are traded under the ticker HXB.MU.

How many employees does AIM ImmunoTech have?▼

As of April 11, 2026, the company has 21 employees.

In which sector is AIM ImmunoTech located?▼

AIM ImmunoTech operates in the Energy sector.

When did AIM ImmunoTech complete a stock split?▼

AIM ImmunoTech has not had any recent stock splits.

Where is AIM ImmunoTech headquartered?▼

AIM ImmunoTech is headquartered in Ocala, United Kingdom.